Bedeutung und Grenzen des PSA in der Diagnose und Verlaufskontrolle des Prostatakarzinoms

  • E. P. Allhoff
Conference paper

Zusammenfassung

Das prostataspezifische Antigen (PSA) wurde von Wang et al. 1979 erstmals isoliert und charakterisiert. Es handelt sich um ein Glykoprotein mit einem Kohlenhydratanteil von annähernd 7%, dessen Polypeptidkette aus 240 Aminosäureresten aufgebaut ist. Sein Molekulargewicht beträgt zwischen 33 000 und 34 000 Dalton1. Die Primärstruktur des PSA, dessen Codierung auf Chromosom 19 erfolgt, zeigt in hohem Maße eine Sequenzhomologie mit anderen Serinproteasen der Kallikrein-Familie (Riegman et al. 1989; Wang et al. 1979; Watt et al. 1986). PSA ist ein physiologisches, organspezifisches Sekretionsprodukt der Epithelzellen von Ductus und Acini der reifen Prostata. Es wird angenommen, daß seine Funktion in der enzymatischen Digestion von Samenblasenproteinen und der Liquifikation des seminalen Koagulums liegt (Lee et al. 1989). Enzymatische Bestimmungen eines erhöhten PSA-Serumwerts reflektieren daher zunächst eine Störung des normalen Sekretionsmechanismus über die Drüsenausführungsgänge der Prostata und einen durch unterschiedliche Ursachen bedingten Übertritt des Glykoproteins in die Zirkulation.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Allhoff EP, De Riese W, Eifinger M, Pethke J, Jonas U (1989) Prostate-specific antigen — comparative clinical appreciation of a serodiagnostic measure after 8 years experience. World J Urol 7:12–16CrossRefGoogle Scholar
  2. Allhoff EP, De Riese W, Gonnermann O et al. (1992) Successful, costeffective algorithm in early detection of prostate cancer (pCa). J Urol 147/4:291AGoogle Scholar
  3. Armitage TG, Cooper EH, Newling DWW, Robinson MRG, Appleyard I (1988) The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 62:584–589PubMedCrossRefGoogle Scholar
  4. Baylin SB, Mendelsohn G (1982) Time-dependent changes in human tumors: implications for diagnosis and clinical behaviour. Semin Oncol 9/4:504–512PubMedGoogle Scholar
  5. Benson MC, Wang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815–816PubMedGoogle Scholar
  6. Brawer MK (1991) Prostate specific antigen. A review. Acta Oncol 30:161–168PubMedCrossRefGoogle Scholar
  7. Breul J, Binder K, Block T, Hartung R (1992) The effect of digital rectal examination on serum concentration of prostate-specific antigen. Eur J Urol (in press)Google Scholar
  8. Carter HB, Andres R, Metter EJ, Fozard JL, Chan DW, Walsh PC (1991) Early detection of prostate cancer using serial PSA measurements. J Urol 145/4:382AGoogle Scholar
  9. Catalona WJ, Smith DS, Ratliff TL et al. (1991) Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161PubMedCrossRefGoogle Scholar
  10. Cooner WH, Mosley BR, Rutherford CL et al. (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146–1154PubMedGoogle Scholar
  11. Deijter SW, Martin JS, McPherson RA, Lynch JH (1988) Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: a comparative evaluation. Urology 32:288–292CrossRefGoogle Scholar
  12. Donohue RE, Miller GJ (1991) Adenocarcinoma of the prostate: biopsy to whole mount. Urol Clin North Am 18:449–452PubMedGoogle Scholar
  13. El-Shirbiny AM, Nilson T, Gleason DF (1987) Immunelectron microscopic localization of prostate-specific antigen in human prostate by the protein A-gold complex. Cancer 60:1288–1293CrossRefGoogle Scholar
  14. Garvin TJ (1990) Re: Prostate infarction associated with aortic and iliac aneurysm repair. J Urol 144:1485PubMedGoogle Scholar
  15. Goldrath DE, Messing EM (1989) Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J Urol 142:1082–1084PubMedGoogle Scholar
  16. Greskovich FJ, Johnson DE, Tenny DM, Stephenson RA (1991) Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade. J Urol 145:798–801PubMedGoogle Scholar
  17. Hortin GL, Bahnson RR, Daft M, Chan K-M, Catalona WJ, Ladenson JH (1988) Differences in values obtained with 2 assays of prostate specific antigen. J Urol 139:762–765PubMedGoogle Scholar
  18. Kabalin JN, Hornberger JC (1991) Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology 37(4):308–310PubMedCrossRefGoogle Scholar
  19. Kiser WR, Clark CA (1991) Measurement of prostate-specific antigen as a screening test for prostate cancer. N Engl J Med 325:963CrossRefGoogle Scholar
  20. Kramer W, Oremek G, Schuldes H, Boeckmann W, Jonas D (1990) Medikamente interferieren mit der PSA-Bestimmung. Urologe [A]29 [Suppl]:A11Google Scholar
  21. Lee C, Keefer M, Zhao ZW, Kroes R, Berg L, Liu XX, Sensibar J (1989) Demonstration of the role of prostate. Specific antigen in semen liquefaction by two-dimensional electrophoresis. J Androl 10:432–438PubMedGoogle Scholar
  22. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE (1991) Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 145:802–806PubMedGoogle Scholar
  23. Meek AG, Park TL, Oberman E, Wiepoloski L (1990) A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 19:733–741PubMedCrossRefGoogle Scholar
  24. Mulders TMT, Bruning PF, Bonfrer JMG (1990) Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker. Eur J Surg Oncol 16:37–41PubMedGoogle Scholar
  25. Oesterling JE, Chan DW, Epstein JI et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766–772PubMedGoogle Scholar
  26. Partin AW, Carter HB, Chan DW et al. (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747–752PubMedGoogle Scholar
  27. Qui S-D, Young CYF, Bilhartz DL, Prescott JL, Farrow GM, He W-W, Tindall DJ (1990) In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144:1550–1556Google Scholar
  28. Riegman PHJ, Vliestra RJ, Klaasen P, van der Korput JAGM, Geurts van Kessel A, Romijn JC, Trapman J (1989) The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 247:123–126PubMedCrossRefGoogle Scholar
  29. Scher HI, Curley T, Geller N et al. (1990) Trimetrexate in prostatic cancer: preliminary observation on the use of prostate. Specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8(11): 1830–1838PubMedGoogle Scholar
  30. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine BA (1987) Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 317:909–916PubMedCrossRefGoogle Scholar
  31. Stamey TA, Kabalin JN, Ferrari M (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol 141:1084–1087PubMedGoogle Scholar
  32. Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM (1988) Neuroendocrine differentiation in prostatic carcinomas. Arch Pathol Lab Med 112:1100–1105PubMedGoogle Scholar
  33. Vesey SG, Goble NM, Stower MJ, Hammonds JC, Smith PJ (1988) The effects of transurethral prostatectomy on serum prostate specific antigen. Br J Urol 62:347–351PubMedCrossRefGoogle Scholar
  34. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17:159–163PubMedGoogle Scholar
  35. Watt KWK, Lee P-J, M’Timkulu T, Chan W-P, Loor R (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci 83:3166–3170PubMedCrossRefGoogle Scholar
  36. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC (1989) The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 141:987–992PubMedGoogle Scholar
  37. Winter HI, Bretton PR, Herr HW (1991) Preoperative prostate-specific antigen in predicting pathological stage and grade after radical prostatectomy. Urology 38:202–205PubMedCrossRefGoogle Scholar
  38. Zagars GK, Sherman NE, Babian RJ (1991) Prostate-specific antigen and external beam radiation therapy in prostate cancer. Cancer 67:412–420PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • E. P. Allhoff

There are no affiliations available

Personalised recommendations